Enterprise Value
-60.07M
Cash
112.7M
Avg Qtr Burn
-19.84M
Short % of Float
0.62%
Insider Ownership
20.55%
Institutional Own.
61.61%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ALG-097558 Details COVID-19 | Phase 2 Initiation | |
ALG-055009 (THR-β Agonist) Details Non-alcoholic steatohepatitis | Phase 2a Data readout | |
ALG-000184 (Capsid Assembly modulator) Details Chronic hepatitis B | Phase 1 Data readout | |
ALG-010133 (S-antigen Transport-inhibiting Oligonucleotide Polymer) Details Chronic hepatitis B | Failed Discontinued | |
ALG-125755 Details Chronic hepatitis B, Liver disease | Failed Discontinued |